查詢結果分析
來源資料
相關文獻
- 高三酸甘油酯導致急性胰臟炎之成因與治療
- 黑鯛第一型類胰島素生長因子之融合蛋白質溶解性的研究
- Genetic Analysis of the Insulin Receptor Gene in Chinese Patients with Extreme Insulin Resistance
- Insulin Resistance in Patients with Klinefelter's Syndrome and Idiopathic Gonadotropin Deficiency
- 談胰島素治療
- Biliary Ascariasis Induced Acute Pancreatitis: A Case Report
- Cloning and Characterization of Insulin-Like Growth Factor I cDNA from Black Seabream (Acanthopagrus Schlegeli)
- 類胰島素生長因子接合蛋白在胚胎學之作用機轉
- Pancreatico-Pleural Fistula--An Unusual Complication of Pancreatitis
- ACARBOSE使用於口服降糖藥物失效之第2型糖尿病患者--臨床評估
頁籤選單縮合
題 名 | 高三酸甘油酯導致急性胰臟炎之成因與治療=Hypertriglyceridemia-Induced Acute Pancreatitis |
---|---|
作 者 | 彭姿蓉; 李銘嘉; 林冠伶; 吳安然; 吳大圩; | 書刊名 | 藥學雜誌 |
卷 期 | 28:2=111 2012.06[民101.06] |
頁 次 | 頁116-120 |
分類號 | 415.542 |
關鍵詞 | 高三酸甘油酯; 胰臟炎; 胰島素; Hypertriglyceridemic; Pancreatitis; Insulin; |
語 文 | 中文(Chinese) |
中文摘要 | 除酒精與膽結石外,高三酸甘油酯血症為急性胰臟炎第三常見的原因。由於至今仍無指引建議治療方式,本文將回顧臨床治療高三酸甘油酯引起急性胰臟炎 (hypertriglyceridemic pancreatitis、HTGP) 的相關文獻。過去文獻曾以胰島素、肝素、分離術 (apheresis) 和口服降血脂藥等治療 HTGP。治療目標為三酸甘油酯小於500 mg/dL。在診斷出 HTGP 48小時內,若有儀器可執行分離術並排除其使用禁忌症下,建議使用分離術治療。此外若血糖大於 500 mg/dL 則建議以靜脈注射胰島素治療,而口服降血脂藥物則於病人可耐受時使用。因肝素的使用仍有爭議,目前不建議用於第一線治療。 |
英文摘要 | Hypertriglyceridemia (HTG) is the third most common cause of acute pancreatitis (AP) after alcohol and gallstones. No official recommendations exist regarding HTGP management and evidence-based data is lacking. Therefore, the purpose of this article is to review the literature of management of HTGP. In addition to the conventional treatment of AP, insulin, heparin, apheresis and oral antihyperlipidemics have been used to treat HTGP. The goal focuses on decreasing serum triglyceride levels less than 500 mg/dL. Apheresis should be started within 48 hours of HTGP diagnosis if readily available at the hospital and the patient has no contraindications such as unstable vital signs or inability to tolerate central venous access. If the patient's glucose is over 500 mg/dL, intravenous insulin can be initiated. Oral antihyperlipidemics should be administered as adjuvant therapy when the patient can tolerate. As the role of heparin is still controversial, it is not recommended to use as a first line agent. |
本系統中英文摘要資訊取自各篇刊載內容。